ReViral Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 22
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $44M
Latest Deal Amount
  • Investors
  • 10

ReViral General Information

Description

Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with the respiratory syncytial virus (RSV) by developing novel compounds.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom

ReViral Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReViral Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 25-Aug-2020 $44M 00000 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series B) 01-Aug-2018 000.00 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC 18-Jul-2017 00.000 000.00 000.00 Completed Startup
4. Early Stage VC 26-Oct-2016 00.000 000.00 000.00 Completed Startup
3. Early Stage VC (Series A) 08-Sep-2015 000.00 0000 Completed Startup
2. Angel (individual) 03-Dec-2014 $1M $1.83M Completed Startup
1. Angel (individual) 26-Feb-2013 $252K $252K 00000 Completed Startup
To view ReViral’s complete valuation and funding history, request access »

ReViral Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 4,355 $0.012895 $99.19 $99.19 $99.19 4.72%
Ordinary 12,400 $0.012895 $6.45 $6.45 $6.45 13.44%
To view ReViral’s complete cap table history, request access »

ReViral Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-cla
Drug Discovery
Stevenage, United Kingdom
22 As of 2020
00000
00000000000 00000

00000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
Brighton, United Kingdom
0 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00

000000 0

at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla par
0000 000000000
Morristown, NJ
0 As of 0000
00.000
00.00 0000-00-00
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReViral Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 0 000.00 0000000000 0 000.00
000000 000000 Accelerator/Incubator Backed Morristown, NJ 0 00.000 0000000000 00.000
000000 000000 Corporation London, United Kingdom 00 00000 000000000 00000
0000 000000000000 Venture Capital-Backed Oxford, United Kingdom 0 000.00 0000000000 000.00
0000000 (000000000 Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
You’re viewing 5 of 9 competitors. Get the full list »

ReViral Executive Team (9)

Name Title Board Seat Contact Info
Stuart Cockerill Ph.D Co-Founder, Chief Scientific Officer & Board Member
Neil Mathews Ph.D Co-Founder & Project Director
Rachel Harland Ph.D Head of Preclinical Development
Seth Hetherington MD Chief Medical Officer
Alex Sapir Chief Executive Officer & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

ReViral Board Members (14)

Name Representing Role Since
Alex Sapir Self Chief Executive Officer & Board Member 000 0000
Chau Khuong OrbiMed Board Member 000 0000
Iain Dukes Ph.D Self Board Member 000 0000
Isaac Manke Ph.D New Leaf Venture Board Member 000 0000
Jason Zhou China Resources Capital Management Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

ReViral Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReViral Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Charoen Pokphand Group Corporation Minority 000 0000 000000 0
China Resources Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Green Sands Equity PE/Buyout Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »